iOncology.ai: India's AI Platform for Cancer Care Shines at BRICS Summit
iOncology.ai, a pioneering AI platform developed by AIIMS and C-DAC, gains international attention at the BRICS Summit for transforming cancer care.
An innovative Indian artificial intelligence platform, iOncology.ai, is gaining international recognition as it is featured in a special issue of the BRICS Health Journal. The platform, developed by the All India Institute of Medical Sciences (AIIMS), New Delhi, and the Centre for Development of Advanced Computing (C-DAC), Pune, aims to revolutionize cancer care.
Spotlight at BRICS Summit
The BRICS Summit, held on September 12-13, showcased iOncology.ai in a review titled "Transforming cancer care in emerging economies: India’s AI innovation." The review, authored by Ashok Sharma and colleagues from AIIMS and C-DAC, highlights the potential of AI in enhancing cancer screening, early diagnosis, and specialist care access.
iOncology.ai is designed to integrate clinical data to support early detection, risk assessment, treatment planning, and longitudinal patient management. The platform is currently undergoing clinical validation and implementation evaluation to determine its effectiveness in real-world settings.
Addressing Global Cancer Care Disparities
Dr. Ashok Sharma emphasized the importance of local innovations like iOncology.ai in bridging cancer-care gaps across the Global South. “Through BRICS collaboration, our focus should be on strengthening cancer prevention, early diagnosis, treatment, and therapy through evidence-based, interoperable solutions tailored to the needs of emerging economies,” he stated.
The review notes that BRICS nations represent over 40% of the global population, with approximately 9 million new cancer cases and 4.66 million deaths annually. It underscores the disparities in cancer incidence and access to care, positioning iOncology.ai within India's expanding digital health and cancer-control infrastructure.
Future Prospects and Challenges
The platform utilizes curated Indian clinical, radiological, and histopathological datasets, with plans to incorporate genetic data and electronic health records. However, iOncology.ai is still in the pilot stage, requiring further multicenter validation to establish its diagnostic accuracy and clinical utility.
This development marks a significant step in India's efforts to enhance healthcare outcomes through technology, with potential implications for other emerging economies. The ongoing research and validation will be crucial in determining the widespread applicability of iOncology.ai in clinical practice.